BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Eleven arrested over mass shooting in South Africa tavern - 2US FDA grants market authorization to six on! PLUS nicotine pouch products
- 3Improving as a Cook: Culinary Experiences in the Kitchen
- 4Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- 5An Aide On Upgrading Your FICO rating
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- At least 18 Palestinians killed in latest clashes in Gaza
- Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- Skeleton of famed musketeer possibly found in Dutch church
- The Most Moving TED Talks You Want to Watch
- Blood pressure drug recalled for possible cross-contamination
- Distributed storage Answers for Information Reinforcement
- Ukraine's new defense minister just outlined how dire its troop shortage has become
